Michael Grimm is a physician scientist specializing in drug development. They completed a residency in cardiology at University Hospital Schleswig-Holstein from 1998 to 2000, followed by a research fellowship at Brigham and Women's Hospital from 2000 to 2002. Over the years, Michael held several key positions in clinical research and development, including Executive Director roles at MyoKardia and AnaptysBio. Currently, they serve as the Head of Metabolic Diseases at Regor Therapeutics Group, a position they have held since 2024.
This person is not in the org chart
This person is not in any teams
This person is not in any offices